Innovation Theater 3
Sponsored By: GSK

---

Program Description

COPD is a heterogenous, progressive and downward spiraling disease which leads to significant number of hospitalizations and/or emergency department (ED) visits. COPD exacerbations that lead to hospitalizations perpetuate this cycle of decline while putting patients at higher risk of poor outcomes including cardiovascular events. Type 2 inflammation, characterized by blood eosinophil count (BEC), further increases the burden of exacerbations and hospitalizations in COPD.

Join a discussion with experts from different facets of pulmonary medicine on the urgency of breaking the cycle of decline in COPD by getting ahead of COPD exacerbations and associated hospitalizations/ED visits, which should be a goal to prioritize for your patients with COPD and Type 2 inflammation.

This is a non-CME event and does not qualify for CME or CE, or MOC credit. This event is not part of the ATS 2025 conference sessions. This event does not reflect the views or opinions of ATS. This program is sponsored by GSK. The information is scientific and non-promotional in nature.

Speakers

Jamie Rutland, MD, FCCP
Rutland Medical Group
Pulmonary and Critical Care Physician
Newport Beach, California

Alberto Papi, MD, PhD
Professor and Chair of Respiratory Medicine
University of Ferrara
Director, Respiratory Unit, Cardio-respiratory Department
Ferrara, Italy

Corinne Young, MSN, FNP-C, FCCP
Colorado Springs Pulmonary Consultants
Nurse Practitioner, Pulmonary and Critical Care
Colorado Springs, Colorado